Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* At least 18 years old at screening and body weight \> 45 kg at screening~* Diagnosed with oHCM consistent with current ACCF/AHA 2011 and meet their recommendations for invasive therapies~* Referred or under active consideration within the past 12 months for SRT procedure and willing to have SRT procedure~* Has documented left ventricular ejection fraction (LVEF) ≥ 60% at Screening~* Has documented oxygen saturation at rest ≥ 90% at Screening~Key Exclusion Criteria:~* Persistent or permanent atrial fibrillation and subject not on anticoagulation for ≥ 4 weeks prior to screening and/or not adequately rate controlled ≤ 6 months prior to screening~* Previously treated with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation \[ASA\])~* For individuals on beta blockers, calcium channel blockers, or disopyramide, any dose adjustment of these medications \< 14 days prior to screening or an anticipated change in regimen during the first 16 weeks of the study~* Any medical condition that precludes upright exercise stress testing~* Paroxysmal, intermittent atrial fibrillation with atrial fibrillation present at screening~* Prior treatment with cardiotoxic agents, such as doxorubicin or similar~* Has a history or evidence of any other clinically significant disorder, condition, or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug: Mavacamten (Type: EXPERIMENTAL): Mavacamten Capsules~Other names:~MYK-461
- Drug: Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo Capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).